Inmazeb (Atoltivimab, Maftivimab, And Odesivimab-Ebgn) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Inmazeb. Always confirm against the full prescribing information.
100 interactions
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Odesivimab.
Level 1 evidence
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Atoltivimab.
Level 1 evidence
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Maftivimab.
Level 1 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Odesivimab.
Level 1 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Atoltivimab.
Level 1 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Maftivimab.
Level 1 evidence
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Atoltivimab.
Level 1 evidence
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Maftivimab.
Level 1 evidence
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Odesivimab.
Level 1 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Atoltivimab.
Level 2 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Odesivimab.
Level 2 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Maftivimab.
Inmazeb (Atoltivimab, Maftivimab, And Odesivimab-Ebgn) has 513 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Inmazeb (Atoltivimab, Maftivimab, And Odesivimab-Ebgn) has 0 major, 36 moderate, and 477 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Inmazeb. Always confirm against the full prescribing information.